Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 955
interventional 821
Observational 127
Registry 7

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 413
Biological 48
Drug|Other 47
Drug|placebo 41
Procedure 35
Other 33
Biological|Drug 32
Drug|Procedure 27
Biological|Drug|Other 24
Behavioral 13
Biological|Other 10
Drug|Other|Procedure 10
Biological|Drug|Procedure 8
Device 8
Other|Procedure 6
Behavioral|Other|Procedure 4
Biological|Procedure 4
Diagnostic Test 4
Dietary Supplement 4
Procedure|Radiation 4
Behavioral|Other 3
Device|Drug 3
Radiation 3
Biological|Drug|Other|Procedure 2
Biological|Other|Procedure 2
Biological|placebo 2
Combination Product 2
Diagnostic Test|Drug 2
Dietary Supplement|Drug 2
Drug|Other|Radiation 2
Drug|Radiation 2
Behavioral|Device 1
Behavioral|Dietary Supplement 1
Behavioral|Genetic 1
Biological|Device 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other|placebo 1
Biological|Drug|placebo 1
Biological|Drug|Radiation 1
Biological|Genetic|Other 1
Biological|Genetic|Other|Procedure 1
Biological|Procedure|Radiation 1
Combination Product|Procedure 1
Device|Other 1
Device|Procedure 1
Drug|Genetic 1
Drug|Genetic|Other 1
Drug|Other|placebo 1
Drug|Procedure|Radiation 1
Genetic 1
Other|Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 396
China 45
France 33
NA 30
United States|Canada 21
Canada 20
Germany 19
United Kingdom 19
Italy 14
Netherlands 13
Korea, Republic of 12
Denmark 11
Spain 9
Belgium 8
India 4
Israel 4
Japan 4
Australia 3
Russian Federation 3
Singapore 3
Sweden 3
United States|Australia 3
United States|United Kingdom 3
Austria|Belgium|Czechia|Germany 2
Belgium|Spain|United Kingdom 2
Denmark|Finland|Norway 2
Egypt 2
France|Germany 2
Greece 2
United States|Belgium|Canada|Spain 2
United States|Belgium|United Kingdom 2
United States|Germany 2
United States|Israel 2
United States|Japan 2
United States|Korea, Republic of 2
United States|Netherlands 2
United States|Spain 2
Algeria|France|Russian Federation|Spain|Ukraine|United Kingdom 1
Australia|Austria|Belgium|France|Germany|United Kingdom 1
Australia|Austria|France|Italy|Netherlands|Portugal|Spain|United Kingdom 1
Australia|Belgium|Spain 1
Australia|Canada 1
Australia|Canada|Hungary|Israel|United States|New Zealand|Poland|United Kingdom 1
Australia|France|Germany|Norway|United Kingdom 1
Australia|New Zealand|United Kingdom 1
Australia|Russian Federation|United Kingdom 1
Australia|Singapore 1
Austria|Belgium|Bulgaria|Canada|Czechia|Denmark|Finland|Israel|Italy|Netherlands|Norway|Poland|Portugal|Slovenia|Spain|Switzerland|United Kingdom 1
Austria|Belgium|China|Denmark|France|Germany|Italy|Korea, Republic of|Norway|Spain|Sweden|United Kingdom 1
Austria|Belgium|Czechia|Denmark|Germany|Ireland|Netherlands|United Kingdom 1
Austria|Belgium|Czechia|France|Germany|Israel|Spain 1
Austria|Belgium|Denmark|Finland|France|Germany|Italy|Japan|Monaco|Spain|Sweden 1
Austria|Belgium|Denmark|Finland|Germany|Italy|Netherlands|Norway|Spain|Switzerland|United Kingdom 1
Austria|Belgium|Denmark|France|Germany|Italy|Netherlands|Norway|Spain|Sweden 1
Austria|Belgium|Denmark|Sweden 1
Austria|Belgium|France|Germany|Italy 1
Austria|Belgium|France|Ireland|Italy|Netherlands|Portugal|South Africa|Spain|United Kingdom 1
Austria|Germany 1
Belarus|Belgium|Bulgaria|Croatia|Czech Republic|Denmark|Finland|Hungary|Latvia|Lithuania|Romania|Russian Federation|Serbia|Slovakia|Sweden|Ukraine 1
Belgium|Bosnia and Herzegovina|Denmark|Finland|France|Germany|Greece|Italy|Netherlands|Norway|Portugal|Spain|Sweden|Turkey 1
Belgium|Canada|Denmark|France|Germany|Israel|Italy|Norway|Poland|Spain|United Kingdom 1
Belgium|Canada|Hungary|Italy|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
Belgium|France|Israel|Italy|Spain|Switzerland|United Kingdom 1
Belgium|Germany 1
Belgium|Germany|Italy|Spain 1
Belgium|Germany|Poland|Russian Federation|Spain 1
Belgium|Italy 1
Belgium|Netherlands|United Kingdom 1
Brazil 1
Brazil|France|Italy|Netherlands|Norway|Russian Federation|Spain|Sweden|United Kingdom 1
Bulgaria|Canada|Czechia|Hungary|Italy|Poland|Spain|United Kingdom 1
Bulgaria|Canada|Denmark|France|Netherlands|Norway|Peru|Portugal|Romania|Russian Federation|Spain|United Kingdom 1
Canada|Denmark|Finland|France|Italy|Sweden 1
Canada|United Kingdom 1
Canada|United States|United Kingdom 1
China|Korea, Republic of 1
China|Malaysia 1
China|United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|France|Germany|Hong Kong|Korea, Republic of|Netherlands|Poland|Russian Federation|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
Cuba 1
Czech Republic|Austria|Belgium|Germany|Italy|Slovakia|Spain|Switzerland|United Kingdom 1
Czechia 1
Czechia|Germany|Poland 1
Czechia|Poland 1
Denmark|France|Germany|Norway 1
Finland 1
France|Italy|United Kingdom 1
Greece|Argentina|Austria|Brazil|Bulgaria|Canada|Denmark|Egypt|Estonia|France|Hong Kong|Hungary|India|Ireland|Israel|Italy|Kuwait|Latvia|Lithuania|Macedonia, The Former Yugoslav Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Serbia|Slovakia|Slovenia|South Africa|Spain|Sweden|Switzerland|Taiwan|Turkey|Uruguay 1
Hungary|Lithuania|Poland|Romania|Russian Federation 1
Italy|United Kingdom 1
Japan|Korea, Republic of 1
Japan|United States|Australia|Belgium|Canada|Czechia|Germany|Italy|Netherlands|Panama|Peru|Spain|United Kingdom 1
Mexico 1
Mongolia 1
Norway 1
Slovakia 1
Spain|United Kingdom 1
Switzerland 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|France|Germany|Greece|Hong Kong|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Philippines|Poland|Portugal|Russian Federation|Singapore|Spain|Switzerland|Taiwan|Ukraine|United Kingdom 1
United States|Argentina|Belgium|Brazil|Canada|Czechia|Hungary|Israel|Italy|Korea, Republic of|Mexico|Poland|Spain 1
United States|Argentina|Brazil|Bulgaria|Chile|Colombia|Greece|Hungary|Mexico|Peru|Poland|Romania|Russian Federation|Spain|Turkey|Ukraine 1
United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Norway|Poland|Russian Federation|Singapore|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Belgium 1
United States|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|Croatia|Czech Republic|Estonia|France|Greece|Hong Kong|India|Israel|Italy|Japan|Korea, Republic of|Latvia|Malaysia|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|Slovenia|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Chile|Colombia|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Russian Federation|South Africa|Spain|Taiwan|Turkey|Ukraine 1
United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Estonia|France|Germany|Israel|Netherlands|Poland|Romania|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|Denmark|Finland|Greece|Ireland|Israel|Italy|Japan|Korea, Republic of|New Zealand|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Israel|Italy|New Zealand|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Poland|Spain 1
United States|Australia|Belgium|Germany 1
United States|Australia|Belgium|Germany|Israel|Poland|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Ireland|Italy|Japan|Korea, Republic of|Russian Federation|Singapore|Taiwan 1
United States|Australia|Belgium|Israel|Italy|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Belgium|Italy|Poland|Russian Federation|Spain|Sweden|Switzerland 1
United States|Australia|Belgium|Italy|Poland|Spain|United Kingdom 1
United States|Australia|Brazil|Canada|China|France|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Canada|Czechia|Italy|Poland|Romania|Russian Federation|Switzerland|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Netherlands|Portugal|Spain|Sweden|Switzerland 1
United States|Australia|Canada|France|Spain|United Kingdom 1
United States|Australia|Germany|Spain|Sweden 1
United States|Australia|Italy|Korea, Republic of|Spain 1
United States|Australia|Singapore 1
United States|Austria|Belgium|Brazil|Bulgaria|Canada|Denmark|Finland|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Peru|Poland|Romania|Spain|Turkey 1
United States|Austria|Belgium|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Norway|Poland|Spain|Sweden|United Kingdom 1
United States|Austria|Belgium|Czechia|Germany|Hungary|Israel|Italy|Spain|Switzerland 1
United States|Austria|Denmark|France|Germany|Italy|Sweden|United Kingdom 1
United States|Belarus|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Greece|Israel|Italy|Netherlands|Norway|Poland|Romania|Spain|Ukraine|United Kingdom 1
United States|Belgium|Bosnia and Herzegovina|Canada|Czechia|France|Ireland|Italy|Russian Federation|Serbia|Spain|Switzerland|United Kingdom 1
United States|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Norway|Poland|Russian Federation|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Belgium|Canada|Denmark|Israel|Italy|Netherlands|Norway|Portugal|Spain 1
United States|Belgium|Czech Republic|France|Germany|Italy|Poland|Russian Federation|Spain|Ukraine 1
United States|Belgium|France|Germany|Netherlands|Spain|Sweden|United Kingdom 1
United States|Belgium|Germany|Italy|Japan|Spain|United Kingdom 1
United States|Belgium|Spain|United Kingdom 1
United States|Brazil|Canada|Czechia|Hungary|Israel|Italy|Poland|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Canada|Israel|Spain|United Kingdom 1
United States|Canada|Japan|Korea, Republic of 1
United States|Canada|Korea, Republic of 1
United States|Canada|Spain|United Kingdom 1
United States|Canada|United Kingdom 1
United States|Denmark 1
United States|Denmark|United Kingdom 1
United States|France 1
United States|France|Italy|Spain 1
United States|Hong Kong|Japan|Korea, Republic of|New Zealand|Singapore 1
United States|Italy|Russian Federation 1
United States|Japan|Korea, Republic of 1
United States|Norway 1
United States|Puerto Rico 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 404
2 51
3 33
4 31
5 25
6 26
7 17
8 16
9 9
10 12
11 10
12 10
13 6
14 7
15 5
16 13
17 10
18 4
19 4
20 6
21 3
22 3
23 4
24 3
25 2
26 3
27 2
28 5
29 1
30 3
31 1
32 1
33 1
34 3
35 1
36 1
38 2
39 2
42 1
45 1
46 4
47 1
48 1
50 2
52 1
55 3
58 1
60 2
61 1
62 2
63 1
64 1
65 1
66 1
67 1
68 2
69 1
70 1
71 1
74 1
75 2
77 1
78 1
81 1
84 2
86 1
90 1
91 1
92 1
93 1
96 1
97 1
103 1
104 1
105 1
113 1
116 1
121 1
123 2
131 1
132 1
136 1
142 1
145 1
151 1
163 1
177 1
192 1
193 1
196 1
204 1
214 1
225 2
242 1
252 1
280 1
298 1
315 1
375 1
390 1
503 1
538 1
573 1
632 1
687 1
1329 1

Phase

Phase Study_Count
Phase 2 326
Phase 1 178
Phase 3 101
N/A 100
Phase 1/Phase 2 81
Early Phase 1 22
Phase 4 9
Phase 2/Phase 3 4

Number of Arms

Number_of_Arms Count_of_Studies
1 396
2 238
3 36
4 20
5 8
6 5
7 2
8 1
37 1
NA 114

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 1.00000 7.000 3.00000 6.00000 1.00000 107.00 10.0000 20
1st Qu. 12.75000 34.000 16.00000 26.50000 32.00000 164.75 265.0000 58
Median 24.00000 76.500 29.50000 50.00000 50.00000 216.00 432.0000 141
Mean 32.09091 281.551 43.87647 74.56962 97.59539 298.25 574.2371 257
3rd Qu. 41.25000 200.000 45.00000 86.00000 99.25000 349.50 733.0000 200
Max. 143.00000 8000.000 588.00000 515.00000 6452.00000 654.00 4312.0000 1190

Trial Group Type

group_type Group_Count
Experimental 913
Active Comparator 154
NA 114
Other 46
Placebo Comparator 43
No Intervention 30
Sham Comparator 3

Intervention Model

intervention_model Study_Count
Single Group Assignment 440
Parallel Assignment 272
NA 75
Sequential Assignment 20
Crossover Assignment 9
Factorial Assignment 5

Primary Purpose

primary_purpose Study_Count
Treatment 696
Diagnostic 36
Supportive Care 35
Prevention 18
Other 11
Basic Science 8
NA 7
Health Services Research 5
Screening 5

Observational Studies

Studies by Country

Country Study_Count
United States 58
China 8
France 8
Germany 5
NA 5
Canada 4
United Kingdom 4
Denmark 3
Korea, Republic of 3
Taiwan 3
Australia 2
Finland 2
Japan 2
Australia|Belgium|Canada|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Portugal|Spain|Switzerland|United Kingdom 1
Austria 1
Austria|Belgium|Germany|Italy 1
Austria|France|Spain|United Kingdom 1
Austria|Germany 1
Belgium 1
Belgium|France|Germany|Italy|Spain 1
Canada|Italy|Spain|United Kingdom 1
China|Hong Kong 1
Egypt 1
El Salvador 1
Greece 1
India 1
Kuwait|Oman|Qatar|United Arab Emirates 1
Netherlands 1
Russian Federation 1
Switzerland 1
United States|Australia 1
United States|Malaysia|Philippines 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 79
2 9
3 3
4 4
5 3
6 4
7 2
9 1
12 1
13 1
14 1
19 1
20 2
22 3
26 1
27 1
28 1
30 1
31 1
65 1
81 1
143 1
144 1
182 1
187 1
199 1
358 1

Enrollment Metrics

Measure Observational
Min 2.0000
1st Qu 60.0000
Median 134.0000
Mean 503.0709
3rd Qu 325.0000
Max 14000.0000

Observation Model

observational_model Study_Count
Cohort 76
Case-Only 22
Case-Control 9
Other 9
NA 5
Case-Crossover 2
Family-Based 2
Case Control 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 88
Retrospective 21
Other 8
NA 6
Cross-Sectional 4

Registries

Studies by Country

Country Study_Count
France 3
Austria 1
Germany 1
Japan 1
United States 1

Sites per Study

Site_count Study_Count
9 1
13 1
14 1
33 1
35 1
68 1
110 1

Enrollment Metrics

Measure Registries
Min 32.0000
1st Qu 125.5000
Median 276.0000
Mean 429.2857
3rd Qu 473.0000
Max 1500.0000

Registry Model

observational_model Study_Count
Cohort 7

Time Perspective

time_perspective Study_Count
Prospective 6
Cross-Sectional 1

Follow-up

target_duration Study_Count
10 Years 2
1 Day 1
12 Months 1
2 Years 1
36 Months 1
84 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03367260 The Treatment Preferences of Women Diagnosed With Ovarian Cancer https://ClinicalTrials.gov/show/NCT03367260 Completed Duke University 2019-01-04
NCT03367182 Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT03367182 Completed Yonsei University 2018-01-31
NCT03275298 Evolution of the Therapeutic Care in Ovarian Cancer From 2011 https://ClinicalTrials.gov/show/NCT03275298 Recruiting UNICANCER 2019-12-31
NCT03155451 Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer. https://ClinicalTrials.gov/show/NCT03155451 Completed RenJi Hospital 2017-10-18
NCT03131102 Perioperative Early Tiredness (Acute Fatigue) in Patients With Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT03131102 Recruiting Charite University, Berlin, Germany 2020-04-30
NCT03119285 Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families https://ClinicalTrials.gov/show/NCT03119285 Recruiting University of Washington 2023-07-31
NCT03082976 Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region https://ClinicalTrials.gov/show/NCT03082976 Completed AstraZeneca 2019-07-24
NCT03019315 The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT03019315 Recruiting National Taiwan University Hospital 2020-12-31
NCT03015376 Inherited Susceptible Genes Among Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT03015376 Recruiting Peking Union Medical College Hospital 2019-01-31
NCT03004391 Development of a Decision Aid to Facilitate Ovarian Cancer Patient’s Choices Regarding Biomarker CA125 https://ClinicalTrials.gov/show/NCT03004391 Recruiting Vejle Hospital 2020-06-30
NCT02981901 Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France https://ClinicalTrials.gov/show/NCT02981901 Active, not recruiting Centre Leon Berard 2019-12-31
NCT02963688 BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT02963688 Completed Samsung Medical Center 2015-12-31
NCT02952521 Ovarian Tumor Biopsies to Study Response to Treatments https://ClinicalTrials.gov/show/NCT02952521 Recruiting University Health Network, Toronto 2021-05-31
NCT02928549 Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study https://ClinicalTrials.gov/show/NCT02928549 Completed Memorial Sloan Kettering Cancer Center 2019-08-26
NCT02916875 Individual Survivorship Program for Ovarian Cancer Patients Based on PROM’s and Shared Decision Making https://ClinicalTrials.gov/show/NCT02916875 Active, not recruiting Vejle Hospital 2018-12-31
NCT02910622 Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer. https://ClinicalTrials.gov/show/NCT02910622 Completed University Hospital, Limoges 2016-06-30
NCT02786147 Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer https://ClinicalTrials.gov/show/NCT02786147 Completed Emory University 2018-02-28
NCT02785731 Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass. https://ClinicalTrials.gov/show/NCT02785731 Completed Angle plc 2017-10-09
NCT02758652 Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT02758652 Recruiting Tampere University Hospital 2026-04-30
NCT02973750 Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer https://ClinicalTrials.gov/show/NCT02973750 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-01-31
NCT00043472 Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk https://ClinicalTrials.gov/show/NCT00043472 Completed National Institutes of Health Clinical Center (CC) NA
NCT00040222 Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer https://ClinicalTrials.gov/show/NCT00040222 Completed National Institutes of Health Clinical Center (CC) NA
NCT03203993 China Ovarian Cancer BRCA Testing Study https://ClinicalTrials.gov/show/NCT03203993 Recruiting AstraZeneca 2026-03-31
NCT04135521 Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer https://ClinicalTrials.gov/show/NCT04135521 Completed Far Eastern Memorial Hospital 2020-03-31
NCT00086567 Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers https://ClinicalTrials.gov/show/NCT00086567 Completed National Institutes of Health Clinical Center (CC) NA
NCT02489058 A Study of Long-Term Responders on Olaparib https://ClinicalTrials.gov/show/NCT02489058 Recruiting University Health Network, Toronto 2020-07-31
NCT02480790 Venous Thromboembolic Complications in Ovarian Cancer https://ClinicalTrials.gov/show/NCT02480790 Active, not recruiting Aalborg University Hospital 2017-05-31
NCT02394015 Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC https://ClinicalTrials.gov/show/NCT02394015 Completed Grupo Español de Investigación en Cáncer de Ovario 2017-12-31
NCT02393898 BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older https://ClinicalTrials.gov/show/NCT02393898 Completed Hoffmann-La Roche 2019-06-14
NCT02343510 Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study https://ClinicalTrials.gov/show/NCT02343510 Completed Ain Shams University 2017-03-31
NCT02341118 Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome. https://ClinicalTrials.gov/show/NCT02341118 Recruiting University Health Network, Toronto 2020-05-31
NCT02262273 OSCA - Olaparib Standard of CAre Study https://ClinicalTrials.gov/show/NCT02262273 Completed AstraZeneca 2016-04-30
NCT02258165 Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer https://ClinicalTrials.gov/show/NCT02258165 Active, not recruiting Queensland Centre for Gynaecological Cancer 2020-08-31
NCT02222883 Prevalence of BRCA in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT02222883 Active, not recruiting AGO Research GmbH 2020-09-30
NCT02151370 An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT02151370 Completed Hoffmann-La Roche 2013-09-30
NCT02122588 OVArian Cancer Non-Interventional Study - OVATAR https://ClinicalTrials.gov/show/NCT02122588 Completed AstraZeneca 2018-05-31
NCT02063464 Blood Collection From People With Ovarian Cancer https://ClinicalTrials.gov/show/NCT02063464 Completed National Institutes of Health Clinical Center (CC) 2016-03-14
NCT01276574 Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT https://ClinicalTrials.gov/show/NCT01276574 Active, not recruiting Turku University Hospital 2020-12-31
NCT02043158 Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer https://ClinicalTrials.gov/show/NCT02043158 Active, not recruiting M.D. Anderson Cancer Center 2020-01-31
NCT02016833 Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity https://ClinicalTrials.gov/show/NCT02016833 Completed PX Biosolutions 2014-06-30
NCT03667417 Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation https://ClinicalTrials.gov/show/NCT03667417 Recruiting Institut Paoli-Calmettes 2028-10-15
NCT02825420 Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients https://ClinicalTrials.gov/show/NCT02825420 Completed PharmaMar 2019-08-31
NCT01982500 Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01982500 Completed Hellenic Oncology Research Group 2016-10-31
NCT01932125 An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01932125 Recruiting Hoffmann-La Roche 2020-11-30
NCT01881451 Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer https://ClinicalTrials.gov/show/NCT01881451 Active, not recruiting British Columbia Cancer Agency 2016-03-31
NCT01869400 An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer https://ClinicalTrials.gov/show/NCT01869400 Completed PharmaMar, Spain 2016-12-31
NCT01863693 An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1) https://ClinicalTrials.gov/show/NCT01863693 Completed Hoffmann-La Roche 2018-06-15
NCT01788995 BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01788995 Completed Hoffmann-La Roche 2018-10-11
NCT01591772 Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer https://ClinicalTrials.gov/show/NCT01591772 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT01544049 Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study https://ClinicalTrials.gov/show/NCT01544049 Completed University of Washington 2018-09-04
NCT01538498 Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer https://ClinicalTrials.gov/show/NCT01538498 Completed National Cancer Center, Korea 2012-11-30
NCT01505829 Diffusion-weighted Imaging Study in Cancer of the Ovary https://ClinicalTrials.gov/show/NCT01505829 Completed Institute of Cancer Research, United Kingdom 2016-12-31
NCT01471483 Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer https://ClinicalTrials.gov/show/NCT01471483 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-11-30
NCT01466049 New Biomarkers Evaluating Ovarian Cancer https://ClinicalTrials.gov/show/NCT01466049 Completed Fujirebio Diagnostics, Inc. 2014-03-31
NCT01422265 Patient Reported Symptoms in Ovarian Cancer (PRECISION) https://ClinicalTrials.gov/show/NCT01422265 Completed Genentech, Inc. 2015-04-30
NCT01384097 An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery https://ClinicalTrials.gov/show/NCT01384097 Completed Charite University, Berlin, Germany 2011-02-28
NCT01372787 Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01372787 Active, not recruiting Gynecologic Oncology Group 2014-01-31
NCT01366183 Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01366183 Active, not recruiting Gynecologic Oncology Group 2019-12-31
NCT04414683 Factors Affecting the Prognosis of Early Ovarian Cancer https://ClinicalTrials.gov/show/NCT04414683 Recruiting Far Eastern Memorial Hospital 2022-01-31
NCT04295577 Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR https://ClinicalTrials.gov/show/NCT04295577 Active, not recruiting Royal Marsden NHS Foundation Trust 2022-02-03
NCT04248231 CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma https://ClinicalTrials.gov/show/NCT04248231 Recruiting Institut Claudius Regaud 2020-09-15
NCT04234243 HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow up https://ClinicalTrials.gov/show/NCT04234243 Completed Instituto de Seguridad Social del Estado de Mexico y Municipios 2017-12-31
NCT04222465 Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT04222465 Recruiting AstraZeneca 2020-12-31
NCT04191252 Genetic Mutation in Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT04191252 Recruiting Peking Union Medical College Hospital 2022-01-01
NCT04190667 Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT04190667 Recruiting Peking Union Medical College Hospital 2021-12-07
NCT04067960 Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer https://ClinicalTrials.gov/show/NCT04067960 Recruiting Mayo Clinic 2020-12-31
NCT03987555 Paclitaxel Therapeutic Drug Monitoring in Cancer Patients https://ClinicalTrials.gov/show/NCT03987555 Recruiting Wake Forest University Health Sciences 2021-03-31
NCT03980028 Role of Surgery in Advanced Ovarian Cancer https://ClinicalTrials.gov/show/NCT03980028 Completed Institut Claudius Regaud 2019-01-01
NCT03943316 Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies https://ClinicalTrials.gov/show/NCT03943316 Recruiting New Mexico Cancer Care Alliance 2020-12-31
NCT03931304 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2) https://ClinicalTrials.gov/show/NCT03931304 Completed Hospices Civils de Lyon 2018-07-31
NCT03921658 The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer https://ClinicalTrials.gov/show/NCT03921658 Recruiting University of Minnesota 2022-10-31
NCT03877796 Clinical Pre-screening Protocol for Ovarian Cancer https://ClinicalTrials.gov/show/NCT03877796 Recruiting Oncology Venture 2021-09-30
NCT03862677 Determining Prognostic Immune Markers in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT03862677 Recruiting Leiden University Medical Center 2022-02-01
NCT03837327 Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy https://ClinicalTrials.gov/show/NCT03837327 Recruiting Venn Biosciences Corporation 2021-04-30
NCT03742856 A Multi-omics Study of Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT03742856 Recruiting Peking Union Medical College Hospital 2020-11-23
NCT03742388 A Genomic Analysis of Evolution of Epithelia Ovarian Tumors https://ClinicalTrials.gov/show/NCT03742388 Recruiting Peking Union Medical College Hospital 2020-12-23
NCT03738319 Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer https://ClinicalTrials.gov/show/NCT03738319 Recruiting Peking Union Medical College Hospital 2019-11-23
NCT03707574 Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study https://ClinicalTrials.gov/show/NCT03707574 Recruiting National Cancer Institute (NCI) 2023-05-01
NCT03691012 Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer https://ClinicalTrials.gov/show/NCT03691012 Recruiting Walter and Eliza Hall Institute of Medical Research 2020-06-30
NCT03656809 Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT03656809 Active, not recruiting NYU Langone Health 2019-03-01
NCT03622385 Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer https://ClinicalTrials.gov/show/NCT03622385 Active, not recruiting Baylor Research Institute 2020-10-31
NCT03614689 Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire https://ClinicalTrials.gov/show/NCT03614689 Recruiting Geneplus-Beijing Co. Ltd. 2019-11-30
NCT03505307 Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) https://ClinicalTrials.gov/show/NCT03505307 Active, not recruiting AstraZeneca 2020-07-31
NCT03491033 Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT03491033 Completed Yonsei University 2017-10-31
NCT01096394 Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer https://ClinicalTrials.gov/show/NCT01096394 Completed Vanderbilt University 2015-10-31
NCT01080521 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy https://ClinicalTrials.gov/show/NCT01080521 Completed Gynecologic Oncology Group 2012-01-31
NCT01042847 How Our Immune System Can Help Fight Cancer https://ClinicalTrials.gov/show/NCT01042847 Completed Winthrop University Hospital 2015-02-28
NCT01037751 M. D. Anderson Symptom Inventory - Ovarian Cancer https://ClinicalTrials.gov/show/NCT01037751 Completed M.D. Anderson Cancer Center 2018-07-18
NCT01000259 Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer https://ClinicalTrials.gov/show/NCT01000259 Recruiting Gynecologic Oncology Group 2100-01-31
NCT00987649 Ovarian Cancer Risk Estimation in Patients With Pelvic Mass https://ClinicalTrials.gov/show/NCT00987649 Completed Fujirebio Diagnostics, Inc. 2010-08-31
NCT00986206 Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer https://ClinicalTrials.gov/show/NCT00986206 Completed Women and Infants Hospital of Rhode Island 2015-07-31
NCT00946140 Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study https://ClinicalTrials.gov/show/NCT00946140 Completed Memorial Sloan Kettering Cancer Center 2013-10-31
NCT00900523 Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT00900523 Completed Vanderbilt-Ingram Cancer Center 2007-07-31
NCT00897442 Collecting Tumor Samples From Patients With Gynecological Tumors https://ClinicalTrials.gov/show/NCT00897442 Completed Gynecologic Oncology Group 2016-01-31
NCT00879840 Assessment of Screening Modalities for Gynecologic Cancers https://ClinicalTrials.gov/show/NCT00879840 Active, not recruiting National Institutes of Health Clinical Center (CC) NA
NCT00829959 Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC) https://ClinicalTrials.gov/show/NCT00829959 Completed M.D. Anderson Cancer Center 2016-08-31
NCT00804258 Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT00804258 Completed City of Hope Medical Center 2012-01-31
NCT04204811 Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT04204811 Recruiting Memorial Sloan Kettering Cancer Center 2020-12-16
NCT02856841 The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer https://ClinicalTrials.gov/show/NCT02856841 Completed Cairo University 2016-06-30
NCT03164980 Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT03164980 Recruiting North Eastern German Society of Gynaecological Oncology 2022-02-28
NCT03124212 Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland https://ClinicalTrials.gov/show/NCT03124212 Recruiting University of Basel 2024-03-31
NCT04152941 Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients https://ClinicalTrials.gov/show/NCT04152941 Active, not recruiting ARCAGY/ GINECO GROUP 2020-01-31
NCT03956095 Study of Nutritional Supplement Shakes in People About to Receive Their Debulking Surgery for Ovarian Cancer https://ClinicalTrials.gov/show/NCT03956095 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT03939481 Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer https://ClinicalTrials.gov/show/NCT03939481 Recruiting Southwest Oncology Group 2025-02-28
NCT00787514 FR in Stored Plasma https://ClinicalTrials.gov/show/NCT00787514 Completed Royal Marsden NHS Foundation Trust 2011-02-28
NCT00757952 Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction https://ClinicalTrials.gov/show/NCT00757952 Completed Pine Street Foundation 2012-12-31
NCT00735150 Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk https://ClinicalTrials.gov/show/NCT00735150 Completed Memorial Sloan Kettering Cancer Center 2010-10-31
NCT00711932 The Effect of TRA-8 on Ovarian Cancer Tissue https://ClinicalTrials.gov/show/NCT00711932 Completed University of Alabama at Birmingham 2012-01-31
NCT00684801 Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers https://ClinicalTrials.gov/show/NCT00684801 Completed Case Comprehensive Cancer Center 2011-12-31
NCT00628654 Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants https://ClinicalTrials.gov/show/NCT00628654 Completed University of California, Davis 2016-03-10
NCT00596349 Women Surviving Ovarian Cancer https://ClinicalTrials.gov/show/NCT00596349 Completed Memorial Sloan Kettering Cancer Center 2009-02-28
NCT00531570 Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma https://ClinicalTrials.gov/show/NCT00531570 Completed NYU Langone Health NA
NCT00525460 Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function https://ClinicalTrials.gov/show/NCT00525460 Completed Dana-Farber Cancer Institute 2014-12-31
NCT00511641 Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer https://ClinicalTrials.gov/show/NCT00511641 Active, not recruiting M.D. Anderson Cancer Center 2020-02-29
NCT00508378 Chemotherapy-Related Toxicities In Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT00508378 Active, not recruiting M.D. Anderson Cancer Center 2020-01-31
NCT00499512 Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00499512 Active, not recruiting M.D. Anderson Cancer Center 2020-08-31
NCT00488878 Data Collection for Patients With Low Grade Ovarian Carcinoma https://ClinicalTrials.gov/show/NCT00488878 Recruiting M.D. Anderson Cancer Center 2034-05-31
NCT00486707 Ovarian Cancer Patient Questionnaire on Genetic Testing https://ClinicalTrials.gov/show/NCT00486707 Completed M.D. Anderson Cancer Center 2008-10-31
NCT00478387 Ovarian Cancer and Immune Response to Flu Vaccine https://ClinicalTrials.gov/show/NCT00478387 Completed University of Pennsylvania 2011-06-30
NCT00368420 Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT00368420 Completed AGO Study Group 2008-07-31
NCT00345709 Elizabeth Registry for Low Grade Ovarian Cancer https://ClinicalTrials.gov/show/NCT00345709 Completed M.D. Anderson Cancer Center 2014-10-31
NCT00315692 Risk of Ovarian Cancer in Patients With a Pelvic Mass https://ClinicalTrials.gov/show/NCT00315692 Completed Fujirebio Diagnostics, Inc. NA
NCT00004909 Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer https://ClinicalTrials.gov/show/NCT00004909 Completed Northwestern University 2002-11-30
NCT00003772 Quality-of-Life Assessment in Patients With Ovarian Cancer https://ClinicalTrials.gov/show/NCT00003772 Completed European Organisation for Research and Treatment of Cancer - EORTC 2001-08-31
NCT00005095 Specimen and Data Study for Ovarian Cancer Early Detection and Prevention https://ClinicalTrials.gov/show/NCT00005095 Recruiting Northwestern University 2020-12-31
NCT00488202 Advanced Ovarian Cancer and Sexuality Phase 1 https://ClinicalTrials.gov/show/NCT00488202 Completed University of British Columbia 2011-08-31
NCT00001938 A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse) https://ClinicalTrials.gov/show/NCT00001938 Completed National Institutes of Health Clinical Center (CC) 2012-12-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03229122 Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA https://ClinicalTrials.gov/show/NCT03229122 Completed AstraZeneca 2018-07-06
NCT02503436 C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population https://ClinicalTrials.gov/show/NCT02503436 Active, not recruiting AstraZeneca 2022-12-31
NCT02302742 Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry https://ClinicalTrials.gov/show/NCT02302742 Recruiting University of Kansas Medical Center 2024-03-31
NCT02163720 Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) https://ClinicalTrials.gov/show/NCT02163720 Completed ARCAGY/ GINECO GROUP 2017-03-31
NCT04027868 Genomic BRCA and Extensive ovArian Cancer Testing https://ClinicalTrials.gov/show/NCT04027868 Recruiting ARCAGY/ GINECO GROUP 2029-12-31
NCT04369352 Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria https://ClinicalTrials.gov/show/NCT04369352 Recruiting Medical University Innsbruck 2023-12-31
NCT01832415 First Line Ovarian Cancer Treatment - Cohort Study https://ClinicalTrials.gov/show/NCT01832415 Completed ARCAGY/ GINECO GROUP 2015-02-28